{"id":"matching-placebo-subcutaneous-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebo is an inert subcutaneous formulation designed to mimic the appearance, administration route, and schedule of an active investigational drug in blinded clinical trials. It allows researchers to isolate the true therapeutic effect of the active agent by controlling for placebo response and other non-specific effects of treatment and observation.","oneSentence":"A placebo injection that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:22.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT07037771","phase":"PHASE3","title":"A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-06-17","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":60},{"nctId":"NCT06727552","phase":"PHASE2","title":"A Study of Barzolvolimab in Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-12-18","conditions":"Atopic Dermatitis","enrollment":131},{"nctId":"NCT05318976","phase":"PHASE2","title":"A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation","status":"COMPLETED","sponsor":"Inmune Bio, Inc.","startDate":"2022-02-28","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":208},{"nctId":"NCT07266402","phase":"PHASE3","title":"A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)","status":"RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2026-01-15","conditions":"Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria","enrollment":240},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT06445023","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-11","conditions":"Chronic Spontaneous Urticaria","enrollment":963},{"nctId":"NCT06603077","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avalo Therapeutics, Inc.","startDate":"2024-09-16","conditions":"Hidradenitis Suppurativa","enrollment":250},{"nctId":"NCT06455202","phase":"PHASE3","title":"A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-07-19","conditions":"Chronic Spontaneous Urticaria","enrollment":976},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT07276581","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT04720534","phase":"PHASE2","title":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-05-31","conditions":"Severe Hypertriglyceridemia","enrollment":229},{"nctId":"NCT06989437","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":982},{"nctId":"NCT06209177","phase":"PHASE1","title":"Study of ARO-CFB in Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2024-04-05","conditions":"IgA Nephropathy","enrollment":49},{"nctId":"NCT06662539","phase":"PHASE2","title":"Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2024-12-09","conditions":"Obesity","enrollment":493},{"nctId":"NCT07190222","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT07190209","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT07487376","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"iBio, Inc.","startDate":"2026-04","conditions":"Overweight , Obesity","enrollment":32},{"nctId":"NCT06468228","phase":"PHASE3","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-27","conditions":"Hidradenitis Suppurativa","enrollment":1280},{"nctId":"NCT07281495","phase":"PHASE2","title":"Taldefgrobep Alfa in Adults With Overweight and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2025-11-24","conditions":"Obesity, Overweight","enrollment":150},{"nctId":"NCT05097287","phase":"PHASE4","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-12-16","conditions":"Asthma","enrollment":1324},{"nctId":"NCT06191315","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-01-03","conditions":"Wheezing, Asthma","enrollment":90},{"nctId":"NCT06632457","phase":"PHASE3","title":"LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-11-07","conditions":"Metabolic Dysfunction Associated Steatohepatitis","enrollment":1590},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis","enrollment":120},{"nctId":"NCT06455449","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-20","conditions":"Polymyositis, Dermatomyositis","enrollment":240},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT06577766","phase":"PHASE1","title":"A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-09-03","conditions":"Obesity, Overweight","enrollment":63},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT07476586","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-04-23","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT06819891","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-12","conditions":"Moderately to Severely Active Crohns Disease","enrollment":425},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT05739383","phase":"PHASE3","title":"A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-09","conditions":"Primary Prevention of Atherosclerotic Cardiovascular Disease","enrollment":14078},{"nctId":"NCT06812988","phase":"PHASE2","title":"Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-28","conditions":"Type 1 Diabetes Mellitus","enrollment":84},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT07390747","phase":"PHASE1","title":"A Trial of SHR-2173 in Healthy Volunteers","status":"RECRUITING","sponsor":"Atridia Pty Ltd.","startDate":"2026-03-06","conditions":"Immunology","enrollment":18},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT05925803","phase":"PHASE3","title":"Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-08","conditions":"Systemic Sclerosis, Scleroderma","enrollment":314},{"nctId":"NCT07090655","phase":"EARLY_PHASE1","title":"A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Climb Bio, Inc.","startDate":"2025-08-11","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT04929210","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-30","conditions":"Arthritis, Psoriatic","enrollment":411},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT07170917","phase":"PHASE2","title":"Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-06","conditions":"Hidradenitis Suppurativa","enrollment":208},{"nctId":"NCT06470048","phase":"PHASE2","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":200},{"nctId":"NCT07167966","phase":"PHASE2","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","status":"NOT_YET_RECRUITING","sponsor":"Paul S. Aisen","startDate":"2026-06-30","conditions":"Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease","enrollment":375},{"nctId":"NCT06834347","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-12","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":210},{"nctId":"NCT06834360","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-06","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":210},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07102628","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-03","conditions":"Acute Coronary Syndrome","enrollment":300},{"nctId":"NCT07455006","phase":"PHASE3","title":"Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-20","conditions":"Thrombocytopenia, Immune","enrollment":60},{"nctId":"NCT06722235","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-27","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":171},{"nctId":"NCT07137598","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-12-05","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05692180","phase":"PHASE3","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-05","conditions":"Asthma","enrollment":200},{"nctId":"NCT06819878","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-17","conditions":"Moderately to Severely Active Crohns Disease","enrollment":600},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT07226050","phase":"PHASE2","title":"CLF065 for Chronic Pouchitis","status":"RECRUITING","sponsor":"Calibr, a division of Scripps Research","startDate":"2026-03-05","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT06588855","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-11","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":350},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT07450378","phase":"PHASE3","title":"QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-05","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":120},{"nctId":"NCT07445919","phase":"PHASE2","title":"A Clinical Study to Evaluate SM17 for Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"SinoMab BioScience Ltd","startDate":"2026-04-05","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT06878261","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT06419374","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH","status":"RECRUITING","sponsor":"89bio, Inc.","startDate":"2024-05-24","conditions":"Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis","enrollment":762},{"nctId":"NCT06883305","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT06023589","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-24","conditions":"Asthma","enrollment":231},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07220811","phase":"PHASE2","title":"Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy","status":"RECRUITING","sponsor":"RAPT Therapeutics, Inc.","startDate":"2025-10-22","conditions":"Ig-E Mediated Food Allergy","enrollment":100},{"nctId":"NCT06934252","phase":"PHASE1","title":"Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients","status":"RECRUITING","sponsor":"TRex Bio, Inc.","startDate":"2025-05-02","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":115},{"nctId":"NCT04023552","phase":"PHASE3","title":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-12","conditions":"Cardiovascular Disease and Lipoprotein(a)","enrollment":8323},{"nctId":"NCT05380453","phase":"PHASE3","title":"Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-29","conditions":"Giant Cell Arteritis","enrollment":151},{"nctId":"NCT07437547","phase":"PHASE2","title":"BPC 157 for Acute Hamstring Muscle Strain Repair","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Hamstring Muscle Strain, Skeletal Muscle Injury","enrollment":120},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT05902598","phase":"PHASE3","title":"A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome","status":"COMPLETED","sponsor":"Visirna Therapeutics HK Limited","startDate":"2023-07-10","conditions":"Familial Chylomicronemia Syndrome","enrollment":37},{"nctId":"NCT07434050","phase":"PHASE3","title":"A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2026-03-09","conditions":"OSA - Obstructive Sleep Apnea, Obesity","enrollment":140},{"nctId":"NCT07219589","phase":"PHASE1","title":"A Single Ascending Dose Study of HM17321 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2025-11-06","conditions":"Obesity, Obese","enrollment":40},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT06790121","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-30","conditions":"Dermatitis Atopic","enrollment":150},{"nctId":"NCT05891496","phase":"PHASE3","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-20","conditions":"Alzheimers Disease","enrollment":23},{"nctId":"NCT06966479","phase":"PHASE2","title":"A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)","status":"RECRUITING","sponsor":"Upstream Bio Inc.","startDate":"2025-05-21","conditions":"Severe Asthma","enrollment":436},{"nctId":"NCT04998201","phase":"PHASE2","title":"Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-09-28","conditions":"Mixed Dyslipidemia","enrollment":353},{"nctId":"NCT07074977","phase":"PHASE2","title":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","status":"RECRUITING","sponsor":"Galderma R&D","startDate":"2025-10-20","conditions":"Chronic Pruritus of Unknown Origin","enrollment":50},{"nctId":"NCT06718101","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-12-19","conditions":"Atopic Dermatitis","enrollment":83},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT04926818","phase":"PHASE3","title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-05","conditions":"Multiple Sclerosis (MS)","enrollment":129},{"nctId":"NCT07248865","phase":"PHASE1","title":"A Phase 1 Study of CLYM116 in Normal Healthy Volunteers","status":"RECRUITING","sponsor":"Climb Bio, Inc.","startDate":"2025-12-02","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT02251431","phase":"PHASE3","title":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction","enrollment":57},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT07167758","phase":"PHASE2","title":"A Study Evaluating TRIV-509 in Atopic Dermatitis","status":"RECRUITING","sponsor":"Triveni Bio","startDate":"2025-08-26","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT07356713","phase":"PHASE1","title":"A Study to Find a Suitable Dose of Exl-111 for Further Research","status":"RECRUITING","sponsor":"Excellergy Inc.","startDate":"2026-01-08","conditions":"Allergic Disease","enrollment":70},{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo, Study Drug"],"phase":"marketed","status":"active","brandName":"Matching Placebo subcutaneous injection","genericName":"Matching Placebo subcutaneous injection","companyName":"Minneapolis Heart Institute Foundation","companyId":"minneapolis-heart-institute-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}